Amgen’s earnings report for the first quarter of 2022 reveals that as some of its biosimilars experienced increased sales, its sales for reference products that are facing biosimilar competition decreased.
Despite sales decreases for its trastuzumab and bevacizumab biosimilars, Amgen’s first quarter (Q1) of 2022 revenues were up overall, including global increases for several biosimilars, according to the company’s earnings report.
The company accumulated $6.2 billion in total revenues, a 6% increase compared with Q1 2021 resulting from 2% growth in global product sales and increased revenue from Amgen’s manufacturing collaboration for COVID-19 drugs.
Biosimilar Performance
According to the report, Amgevita (adalimumab-atto) was the most prescribed adalimumab biosimilar throughout Europe. From Q1 2021 to Q1 2022, the biosimilar had increased year-over-year sales of 2%, caused by 16% volume growth. The increase in net sales was partially offset by foreign exchange impact and lower net selling price resulting from increased competition from other adalimumab biosimilars. In the European Union, there are 10 adalimumab biosimilars competing with the reference product (Humira).
Net sales for Mvasi (bevacizumab-awwb) decreased 17% year-over-year, which the company attributed to lower net selling price, partially offset by 13% volume growth. Mvasi is 1 of 3 bevacizumab biosimilars in the United States. The European Union has 7 bevacizumab biosimilars referencing Avastin including Mvasi. Amgen said that it expects that Mvasi’s net selling price and volume declines driven by increased competition will continue to erode.
Kanjinti (trastuzumab-anns) was the highest selling trastuzumab biosimilar in the United States, where it is 1 of 5 FDA-approved biosimilars for Herceptin. However, the global sales for the drug decreased 40% year-over-year due to the same reasons that sales for Mvasi decreased. In the European Union, there are 6 trastuzumab biosimilars approved for marketing.
Amgen combined the sales for Avsola (infliximab-axxq) and Riabni (rituximab-arrx) with Gensenta, Imlygic, Corlanor, and Bergamo into the “other products” category. The sales for this group increased by 18% between Q1 2021 and Q2 2022.
Reference Product Performance
Amgen reported that year-over-year net sales decreased by 7% and the year-over-year volume remained flat during Q1 2022 for Enbrel (etanercept). The company said this was due to declines in net price and inventory levels. Although Enbrel will not face any biosimilar competition in the United States until 2029, the drug is competing against 3 etanercept biosimilars in the European Union.
In the report, Amgen combined the sales for Neulasta (pegfilgrastim), Neupogen (filgrastim), and Epogen (epoetin alfa) with other “established products,” including Aranesp, Parsabiv, and Sensipar/Mimpara. The sales for these products amounted to $970 million during Q1 2022, representing a 12% year-over-year decrease. Neulasta, Neupogen, and Epogen all face biosimilar competition in the United States and European Union, and Amgen said that it expects that net price and volume erosion will continue.
Amgen’s Biosimilar Pipeline
Amgen updated investors on its 4 biosimilars in development, including Amgevita. Although the drug is marketed in Europe and approved by the FDA, the company is conducting a phase 3 study that will provide data to support an interchangeability designation in the United States.
If granted, pharmacists will be able to automatically switch out Humira for the biosimilars without needing to seek provider permission. Amgevita is anticipated to be the first adalimumab biosimilar to enter the US market in January 2023, where it will be marketed as Amjevita.
Additionally, phase 3 studies evaluating the safety and efficacy of biosimilars referencing Stelara (ustekinumab), Eylea (aflibercept), and Soliris (eculizumab) are in progress. The company is also conducted a phase 3 analysis to support interchangeability for its ustekinumab biosimilar (ABP 654). Data for the studies assessing ABP 938 (aflibercept biosimilar) and ABP 959 (eculizumab biosimilar) are expected to be completed in 2022.
BioRationality: Withdrawal of Proposed Terminal Disclaimer Rule Spells Major Setback for Biosimilars
December 10th 2024The United States Patent and Trademark Office (USPTO)’s withdrawal of its proposed terminal disclaimer rule is seen as a setback for biosimilar developers, as it preserves patent prosecution practices that favor originator companies and increases costs for biosimilar competition, according to Sarfaraz K. Niazi, PhD.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Pertuzumab Biosimilar Shows Promise in HER2-Positive Breast Cancer Treatment
December 9th 2024The proposed pertuzumab biosimilar QL1209 demonstrated equivalent efficacy and safety to reference pertuzumab (Perjeta) in neoadjuvant treatment of HER2-positive, ER/PR-negative early or locally advanced breast cancer, offering a cost-effective alternative with comparable clinical outcomes.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Aflibercept Biosimilar MYL-1701P Provides Equivalence in DME Therapy
November 27th 2024The study findings demonstrate that the aflibercept biosimilar MYL-1701P is as effective and safe as the reference aflibercept in treating diabetic macular edema (DME), offering a promising option for reducing treatment costs and improving global access to care for patients with DME.
Ocrelizumab Biosimilar Shows Equivalent Efficacy as Multiple Sclerosis Treatment
November 26th 2024The phase 3 trial (NCT04966338) found that a biosimilar ocrelizumab candidate (Xacrel) was equivalent to Ocrevus in reducing the annualized relapse rate and showed comparable safety and efficacy in treating relapsing multiple sclerosis over 96 weeks.